Foundayo vs Wegovy: Comparing the Leading Weight Loss Treatments
The approval of Foundayo has given patients a new option in the weight loss medication landscape, previously dominated by injectable GLP-1 drugs like Wegovy (semaglutide). But how does this new oral pill compare to the established injectable treatment? We break down the key differences.
Efficacy: Weight Loss Results
Both medications have shown impressive results in clinical trials, though they take different approaches to achieving them.
- Foundayo: Average weight loss of 22% of body weight over 68 weeks in Phase III trials
- Wegovy: Average weight loss of 15-17% of body weight over 68 weeks based on the STEP trial program
On paper, Foundayo appears to have the edge in raw weight loss numbers. However, experts caution that direct head-to-head trials have not yet been completed, and patient populations in the studies may have differed.
Administration and Convenience
This is where the biggest practical difference lies. Wegovy requires a weekly subcutaneous injection using a prefilled pen, while Foundayo is a once-daily oral tablet taken with water on an empty stomach.
For many of my patients, the idea of weekly self-injections is a significant barrier to starting treatment. An effective pill option could dramatically improve treatment adherence and reach many more patients who need help.
A survey conducted by the Obesity Action Coalition found that 68% of adults with obesity would prefer an oral medication over an injectable, even if the injectable were slightly more effective.
Side Effects Profile
Both drugs share a similar side effect profile due to their GLP-1 mechanism of action. Nausea is the most common complaint with both medications, though Foundayo reported slightly higher rates of gastrointestinal issues during the dose escalation phase. Serious side effects remain rare with both treatments.
Cost Considerations
Wegovy currently carries a list price of approximately $1,350 per month. Foundayo pricing has not been finalized, but analysts project it will fall between $800 and $1,200 monthly. Insurance coverage will be a major factor for most patients, and formulary decisions are still pending at most major health plans.
The Bottom Line
Both Foundayo and Wegovy represent significant advances in obesity treatment. The choice between them will likely come down to patient preference regarding administration method, insurance coverage, and individual response to treatment. Physicians recommend discussing both options with your healthcare provider to determine the best fit for your specific situation.
